<?xml version='1.0' encoding='utf-8'?>
<document id="28371445"><sentence text="Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide."><entity charOffset="52-77" id="DDI-PubMed.28371445.s1.e0" text="Sorafenib-β-D-Glucuronide" /></sentence><sentence text="The oral multikinase inhibitor sorafenib undergoes extensive UGT1A9-mediated formation of sorafenib-β-D-glucuronide (SG)"><entity charOffset="31-40" id="DDI-PubMed.28371445.s2.e0" text="sorafenib" /><entity charOffset="90-115" id="DDI-PubMed.28371445.s2.e1" text="sorafenib-β-D-glucuronide" /><entity charOffset="117-119" id="DDI-PubMed.28371445.s2.e2" text="SG" /><pair ddi="false" e1="DDI-PubMed.28371445.s2.e0" e2="DDI-PubMed.28371445.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28371445.s2.e0" e2="DDI-PubMed.28371445.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28371445.s2.e0" e2="DDI-PubMed.28371445.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28371445.s2.e1" e2="DDI-PubMed.28371445.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28371445.s2.e1" e2="DDI-PubMed.28371445.s2.e2" /></sentence><sentence text=" Using transporter-deficient mouse models, it was previously established that SG can be extruded into bile by ABCC2 or follow a liver-to-blood shuttling loop via ABCC3-mediated efflux into the systemic circulation, and subsequent uptake in neighboring hepatocytes by OATP1B-type transporters"><entity charOffset="78-79" id="DDI-PubMed.28371445.s3.e0" text="SG" /></sentence><sentence text=" Here we evaluated the possibility that this unusual process, called hepatocyte hopping, is also operational in humans and can be modulated through pharmacological inhibition" /><sentence text=" We found that SG transport by OATP1B1 or murine Oatp1b2 was effectively inhibited by rifampin, and that this agent can significantly increase plasma levels of SG in wildtype mice, but not in Oatp1b2-deficient animals"><entity charOffset="86-94" id="DDI-PubMed.28371445.s5.e0" text="rifampin" /><entity charOffset="15-22" id="DDI-PubMed.28371445.s5.e1" text="SG" /><entity charOffset="160-167" id="DDI-PubMed.28371445.s5.e2" text="SG" /><pair ddi="false" e1="DDI-PubMed.28371445.s5.e1" e2="DDI-PubMed.28371445.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28371445.s5.e1" e2="DDI-PubMed.28371445.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28371445.s5.e1" e2="DDI-PubMed.28371445.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28371445.s5.e0" e2="DDI-PubMed.28371445.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28371445.s5.e0" e2="DDI-PubMed.28371445.s5.e2" /></sentence><sentence text=" In human subjects receiving sorafenib, rifampin acutely increased the systemic exposure to SG"><entity charOffset="29-38" id="DDI-PubMed.28371445.s6.e0" text="sorafenib" /><entity charOffset="40-48" id="DDI-PubMed.28371445.s6.e1" text="rifampin" /><entity charOffset="92-99" id="DDI-PubMed.28371445.s6.e2" text="SG" /><pair ddi="false" e1="DDI-PubMed.28371445.s6.e0" e2="DDI-PubMed.28371445.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28371445.s6.e0" e2="DDI-PubMed.28371445.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28371445.s6.e0" e2="DDI-PubMed.28371445.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28371445.s6.e1" e2="DDI-PubMed.28371445.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28371445.s6.e1" e2="DDI-PubMed.28371445.s6.e2" /></sentence><sentence text=" Our study emphasizes the need to consider hepatic handling of xenobiotic glucuronides in the design of drug-drug interaction studies of agents that undergo extensive phase II conjugation"><entity charOffset="74-86" id="DDI-PubMed.28371445.s7.e0" text="glucuronides" /></sentence><sentence text="" /></document>